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ABSTRACT 
Mary Grace Stewart: The Effect of Histone Deacetylase Inhibitors on Metastatic Breast Cancer Cells in Conjunction 
with Clinically Relevant Chemotherapeutic Agents (Under the direction of Dr. Yu-Dong Zhou and Dr. Dale George Nagle) 
 
Histone Deacetylases (HDACs) are enzymes charged with the job of loosening DNA 
packaged around histone proteins. This gives them the opportunity to affect the 
transcriptional regulation of certain cancer associated genes and proteins, but HDACs are not 
limited to only DNA modification. They also target non-chromatin proteins in the cytoplasm, 
and have been closely linked to the many pathways involved in metastatic breast cancer such 
as apoptosis evasion, cell migration, and angiogenesis. HDAC’s effect on important 
cytoplasmic proteins could play a huge role in the largely unknown mechanisms of metastatic 
breast cancer. HDAC inhibitors are a rising class of chemotherapeutic agents. In this 
research, HDAC inhibitors selective for cytoplasmic target proteins are used in conjunction 
with nuclear based HDAC inhibitors and known microtubule stabilizers and destabilizers to 
test and explore the effects of HDAC inhibition on MDA-MB-231-derived metastatic breast 
cancer cell lines BoM-1833 (BoM) and LM-4175 (LM), and in MCF-7-derived metastatic 
breast cancer cell line MCF-7 BoM. Through viability, clonogenic, and combination assays, 
the HDAC inhibitors were not found to have complete inhibition of the tumor cells at any of 
the tested concentrations but show a trend suggesting potential effects on tumor inhibition at 
higher concentrations. There is also some evidence supporting a potential significance of 
HDAC inhibitors on ER+ breast cancer cells. Clonogenic assays upheld the inhibitory results 
of HDAC inhibitors on metastatic breast cancer cells, and emphasized the increased 
effectiveness of higher concentrations of HDAC inhibitors. Combination assays showed a 
trend towards antagonistic effects between HDAC inhibitors and microtubule stabilizes. 
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INTRODUCTION:  
BREAST CANCER:  
In 2019, the American Cancer Society predicts that there will be 1,762,450 new 
cases of breast cancer in the United States. Of these, 42,260 cases are predicted to end in 
death [1]. In 2018, The World Health Organization’s International agency for Cancer 
Research documented an estimated 2,088,849 cases with 626,679 deaths worldwide. Breast 
cancer has the most incidences worldwide behind lung and skin cancers [2].  From 1989 to 
2016, death associated with breast cancer in the U.S. was reduced by 40%. This is likely 
attributed to increased awareness, earlier diagnosis, and better available treatments, but 
since 2016, the death rates for women under 50 have plateaued [1].  Something new needs 
to happen. Early intervention can only go so far to help women, and with a 0.4% incident 
increase in the U.S. per year over recent years [1], one would expect the death rates to 
begin climbing again in the future if something new doesn’t intervene.  
 Breast cancer, along with most all cancers, is caused by abnormal, out of control 
cell growth. In breast cancer, the growth and invasion of the cancerous cells can be denoted 
by staging. Small localized cancerous tumors in the breast duct or the mammary glands 
that have not spread or have spread minimally to the most commonly cancer associated 
lymph node, the sentinel lymph node, are classified as stage 1 breast cancer. Stage 2 tumors 
are larger and have generally spread to a few more nearby lymph nodes. Stage 3 tumors 
are even larger and have spread to most all nearby lymph nodes or have begun growing 
into the nearby skin and muscle tissues surrounding the breast. Stage 4 is metastatic breast 
cancer, which spreads to other parts of the body [4] (figure 1.1).  
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Figure 1 Stages of Breast Cancer (Siddique, M. (2017, April)) 
Breast tumors present as a mass or lump in the breast. The mass is usually hard and 
irregular and isn’t associated with pain, but some can be soft, round, and painful. This is 
why diagnostic tools are so important. Most healthcare specialists use mammograms, 
specialized x-rays that can help visualize breast tissue and structures, and biopsies to 
identify the malignancy of tumors. These and more technological advances have helped to 
detect disease early on and reduce the incidence of metastasis. If caught early enough, these 
cancers can be very treatable. Some examples of treatments are chemotherapy, hormone 
therapy, targeted drug therapy, and oncoplastic surgery, in which the surgeon has to remove 
a tumor but reconstructs the breast afterward. The removal of a tumor from the breast is 
called a lumpectomy, which, along with partial mastectomies, can be done with early stage 
tumors. Later stage, larger tumors require full mastectomies and full reconstruction [4].  
 Clinically, breast cancer tumors can be classified by their genetic variation and 
receptor types. They can be broken down into four subgroups: luminal A, luminal B, Her2+ 
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(human epidermal growth factor receptor 2-positive), and basal-like. Luminal A breast 
tumors have estrogen and progesterone receptors and can be treated with hormone therapy 
and chemotherapy. Luminal B tumors have estrogen receptors and are Her2 positive. These 
are generally treated with chemotherapy, hormone therapy, and targeted Her2 therapy. 
Her2+ tumors do not have hormone receptors but are positive for the Her2 oncogene which 
codes for a growth promoting Her2 protein. These tumors are approached with targeted 
therapy to shut down the Her2 protein in addition to chemotherapy [5]. Basal-like tumors 
are “triple-negative.” They don’t have estrogen receptors or progesterone receptors, and 
they do not overexpress Her2. Often, mutations in the BRCA1 gene, a tumor suppressor 
gene, are associated with triple-negative breast cancer. These are difficult to treat because 
there are no available target proteins or receptors for therapy. Chemotherapy is the 
treatment choice for basal like tumors. These are usually larger and more severe at 
presentation and are typically diagnosed with poorer overall outcomes [6]. Another, less 
common type of breast cancer is inflammatory breast cancer (IBC) which is associated 
with advanced stage presentation and axillary lymph node involvement which leads to a 
greater chance of metastasis. About 35% of IBC cases have distant metastasis which may 
be contributed to increased levels of Her2 protein and pro-angiogenic factors. There are so 
many types of breast cancer because the tumors have such heterogeneous pathology and 
genetic profiles [7].  
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METASTASIS: 
 When breast cancer cells break off the primary tumor, they can enter into the 
lymphatic or blood vasculature and disseminate to other organs. This is known as 
metastasis or stage 4 breast cancer. Breast cancer cells generally metastasize to the bones, 
lungs, liver, and brain. Some cases of metastasis present at initial diagnosis, which is 
known as de novo metastasis and generally results from a late diagnosis, but most occur 
after an initial diagnosis and treatment course. Some breast cancer cells can evade 
treatment and travel to other organs [8]. It is important to note that cancer that has 
metastasized to the bone, for example, is not bone cancer. It is still breast cancer and has 
the same genetic makeup as the primary breast tumor. 
 In order to travel over the body, epithelial breast cancer cells have to undergo a 
differentiation into mesenchymal stem cells. This differentiation is known as epithelial–
mesenchymal transition (EMT.) The EMT process is reversible and it plays an important 
intrinsic role in organ development, wound healing, and fibrosis. The reversible nature of 
EMT makes it a source of interest when looking at possible drug targets. The shift from 
epithelial cells to mesenchymal stem cells results in a decrease in cell adhesions, and 
increase in cytoskeleton arrangement, matrix remodeling, and motility. Mesenchymal cell 
motility comes from specialized spindle morphology and cytoskeleton features [9]. There 
are two schools of thought on the factors that promote dissemination. Some believe in early 
dissemination and the importance of the microenvironment for selecting signaling 
pathways which lead to metastasis. Others believe in late dissemination in which the 
gradual mutation of the primary tumor results in the ability to metastasize [10]. Critical 
steps in the initial stages of EMT are the downregulation or silencing of E-cadherins, cell-
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cell adhesion proteins, and the upregulation of N-cadherins and matrix metalloproteinases 
(MMPs), proteases that cleave endothelium proteins [11]. These steps work to break the 
cancer cells away from the surrounding epithelial cells and help them degrade and weaken 
the surrounding extracellular matrix (ECM). Once converted into mesenchymal stem cells, 
the MMP enzymes break down the extracellular matrix and deregulate ECM remodeling 
which allows the tumor to more easily invade local tissues [9]. The MMPs also help to 
break down the endothelial cells of lymphatic and blood vasculature. Due to tumor 
mediated angiogenesis, the blood vessels near the tumor are usually more permeable and 
leaky. Once inside the vasculature, the breast cancer cells are vulnerable to immune attack. 
They evade this by surrounding themselves with platelets and clotting factors. This most 
likely serves a dual purpose by also protecting the cells from anoikis, a form of apoptosis 
induced by the loss of cell-to-cell adhesions. Once safely in platelet clumps, the cancer 
cells travel within the vasculature until they come to a target organ with an ideal 
microvasculature, where the cancer cells attach to the wall of the blood or lymph vessels. 
Extravasation usually happens when a platelet clump associated with tumor cells is 
attracted to a weakened part of target organs microvasculature. The MMPs help to go 
through the endothelium of the vessels and into the parenchyma of the target organ [10]. 
The mesenchymal cells may then differentiate back into epithelial cancer cells in order to 
proliferate and form a tumor (figure 1.2). The target organ microenvironment must be 
conducive for proliferation, for example, the growth factor VEGF (vascular endothelial 
growth factor) is required to help ensure angiogenesis to support the newly growing 
secondary tumor [10]. This idea is known as the “seed and soil” theory. The 
microenvironment of the “soil” has to be specifically suited to the “seed” for it to grow 
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[11]. One major example of an extrinsic factor of microenvironment associated with breast 
cancer metastasis is hypoxia and hypoxia-inducible factors (HIFs.) These factors, 
specifically HIF-1 help promote motility, intravasation, platelet clumping in the 
vasculature, and formation of proper “soil” for metastatic invasion [11].  
 
 
 
 
 
 
 
  
Figure 2 The significance of EMT and MET in breast cancer tumor metastasis 
Ruben, B. (2015, June 22) 
 
Secondary symptoms can precede a diagnosis of metastatic breast cancer. 
Headaches, seizures, and drowsiness are associated with brain metastasis. Pain and 
frequent fracturing can be a symptom of bone metastasis. In the liver, metastasis presents 
with jaundice and a swelling of the abdomen. Lung metastasis is associated with chronic 
shortness of breath. Treatment plans to address metastasis are often primarily aimed at 
helping prolong and improve the quality of remaining life [12]. That means that all such 
treatments can do to address metastasis is treat symptoms and prevent further spreading of 
the cancer. Metastasis is sometimes approached surgically, but generally, based on the type 
of primary cancer, it is treated with hormone therapy or chemotherapy. There are some 
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newer targets that have been explored to help treat metastasis. Bevacizumab is a 
monoclonal antibody to VEGF. It is an antiangiogenic therapy used to prevent the 
formation of new blood vessels around tumors. It has shown an increase in progression-
free survival time. Unfortunately, bevacizumab is a high-risk option specifically for breast 
cancer patients. It is associated with hemorrhaging, severely elevated blood pressure, and 
heart failure in breast cancer patients [10]. Another new drug therapy is called trastuzumab 
(Herceptin). It is a monoclonal antibody of the Her2+ antigen. This therapy has proven 
effective in metastasis of Her2+ cancers [10]. There remains considerable room for 
research and development in treating metastatic breast cancer.  
 
HISTONE DEACETYLASES:  
 Eukaryotic DNA is packaged tightly together in the nucleus of every cell. Strands 
of DNA wrap around positively charged proteins rich in lysine and arginine called histones. 
The positive charge of histones helps to stabilize the negatively charged DNA. A histone 
octamer wrapped with 146 DNA base pairs, that make up a nucleosome. The octamer 
contains pairs of four core histones: H3, H4, H2A, and H2B. An H1 histone helps to ensure 
the DNA is wrapped effectively around the nucleosome [13]. A nucleosome is a subunit of 
chromatin, which coils tightly to form a eukaryotic chromosome.  
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Figure 3 Histone structure and organization (Silk, E. (2017, May 25)) 
Transcriptional regulation is strongly influenced by the packaging of the DNA. 
Histone modifications can affect the accessibility of DNA and therefore the expression of 
genes. Acetylation is one of the ways that histones are modified. Histone acetyltransferase 
protein can acetylate the tail of histones in a nucleosome. The acetylation occurs at the ε-
amino group of conserved lysine residues at the N-terminal of histone tails. In vivo, all core 
histones are acetylated, but H3, and H4 tails are more commonly acetylated than those of 
H2A/H2B dimers [14]. The added acetyl group acts to mask the positivity of the histones, 
loosening the tightly wrapped negatively charged DNA and exposing it for transcription. 
Therefore, generally, hyperacetylation results in an increase of gene expression, whereas, 
hypoacetylation results in the opposite effect [14].  
 Acetylation of histone tails is reversible and balanced by the activities of histone 
acetyltransferases (HATs), and histone deacetylases (HDACs), which deacetylate the 
histone tails [15]. In humans, there are 18 HDACs which are divided into four classes [13]. 
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Class I is made up of HDAC 1, HDAC 2, HDAC 3, and HDAC 8. These are Rpd3-like 
proteins, meaning they have a similar mechanistic profile as that of the protein in Rpd3 
yeast [15]. Class I HDACs are generally located in the nucleus and are ubiquitously 
distributed throughout the body [16]. Class II consists of HDAC 4, HDAC 5, HDAC 6, 
HDAC 7, HDAC 9, and HDAC 10. HDAC 10 and HDAC 6 are slightly different than the 
rest in this class and so are subdivided as Class IIb. All of these are Hda-1-like proteins, 
meaning they are similar to the Hda-1 yeast protein [15]. They can be moved between the 
nucleus into the cytoplasm, which suggests a potential for involvement with non-histone 
proteins. These HDACs are also expressed in a more tissue-specific fashion than Class I 
[16]. Class IV, as of now, is made up of only HDAC 11 and is homologous to Class I and 
II [15]. These three classes (I, II, IV) are known as the classical families (Table 1) [14].  
Class III HDACs are Sir2-like proteins and have a mechanism involving NAD+, where the 
classical families have a zinc-dependent mechanism for deacetylation [15].  
 
        Table 1 Classical Families of histone 
Class I HDAC 1-3 
HDAC 8 
Class II HDAC 4-7 
HDAC 9,10 
Class IV HDAC 11 
 
 Not only can HDACs regulate gene expression through direct deacetylation of 
histones, they can also act in corepressor complexes with nuclear receptors, in direct 
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interaction with transcription factors, and in the deacetylation of non-histone proteins, 
making it possible for them to alter regulation of important cell functions and cellular 
homeostasis [16]. Specific HDACs have been linked to metabolic, inflammatory, 
immunological, cardiac, pulmonary, and neurodegenerative diseases, as well as cancer 
[15].  The loss of acetyl groups on Lys16 and the trimethylation of Lys20 of Histone 4 has 
been found to be a common event in human cancers. Methylation acts in opposition to 
acetylation. The reduction of acetylation of certain histones has also been more specifically 
linked to tumor invasion and metastasis [16]. Further exemplifying the relationship 
between HDACs and cancer, some gastric, prostate, colon, and breast cancer tumor 
samples have been found to have increased levels of HDAC 1. Similarly, HDAC 3 and 
HDAC 6 have been linked closely to colon and breast cancer. The increased levels of 
HDACs in tumor cells points to a potential involvement in the transcriptional repression of 
tumor suppressor genes [16]. They are also associated with cancer cell progression and 
metastasis through the modification of non-histone proteins. One example is the 
transcription factor SNAIL which recruits HDAC 1 and HDAC 2 along with their 
corepressor complex to repress the expression of E-cadherin, a crucial player in EMT [16]. 
Another non-histone target of HDACs closely linked to cancer is p53, an important tumor 
suppressor protein involved in the cell cycle. The deacetylation of p53 promotes its 
ubiquitination (degradation.) Without p53, cells can reenter the cell cycle with limited 
restriction. This contributes to cancer cell proliferation and tumor growth [15]. Tumor 
angiogenesis has also been associated with an increase in HDAC and their deacetylation 
and promotion of HIF-1〈, VEGF, and MMPs which are all important proteins associated 
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with tumor invasion [15]. All of this points to HDACs as prime drug targets for metastatic 
cancers.  
 HDAC 6 is unique in its tendencies to stay in the cytoplasm and primarily 
deacetylate non-histone proteins instead of chromatin proteins involved with gene 
expression [17]. Among many proteins that HDAC 6 is known for targeting are alpha-
tubulin, cortactin, Hsp90 (heat shock protein 90), ®-caderin, and survivin. These proteins 
are associated with cell migration, F-actin binding, protein degradation, cell proliferation, 
and suppression of apoptosis respectively [17]. Hypoacetylation of alpha-tubulin promotes 
chemotactic cell movement. HDAC 6 appears to play a big role in tumor metastasis. One 
indication of this idea is the relationship between HDAC 6 and human enhancer 
filamentation 1(HEF1), a prometastatic scaffolding protein which phosphorylates HDAC 
6, enhancing tubulin deacetylase activity and regulating cilia assembly by HDAC 6 [17]. 
Another role HDAC 6 plays in cells is colocalizing with G-Protein-Coupled Receptor 
Kinase 2 (GRK2) and interacting in the lamellipodia of migrating cells. The increased 
deacetylation of local tubulin proteins increases motility. HDAC 6 is required to modulate 
the invadopodia activity and invasion in many types of cancer. There is a significant link 
between higher levels of HDAC 6 in breast cancer cells and metastasis, which corresponds 
to the role it seems to play in the migration and movement of the cell. It also promotes 
angiogenesis by deacetylating cortactin in endothelial cells, helping to regulate migration 
and sprouting of cancer cells. Additionally, it has been found to upregulate HIF-1 and 
VEGF, both highly involved proteins in tumor angiogenesis [17]. HDAC 6 is also linked 
with cell proliferation.  HDAC 6 associates with the transcription factor Runt Related 
Transcription Factor 2 (RunX2) which results in the repression of p21, a vital protein in 
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the cell cycle. The cylindromatosis (CYLD) gene, is a deubiquitinating enzyme and tumor 
suppressor gene. It controls cells growth, division, and cytokinesis through a-tubulin and 
microtubules. It also inhibits HDAC 6. Many types of cancers are found to have decreased 
levels of CYLD [17]. The regulation and repression of HDAC 6 may be a target to help 
increase expression of CYLD. In addition to proliferation and migration of the cell, HDAC 
6 is involved in apoptosis. They regulate the Ku70 protein through deacetylation, 
preventing apoptosis. They also regulate the oncogenic protein survivin, which is expressed 
primarily in ER+ breast cancer. Survivin is acetylated in the nucleus, which masks its anti-
apoptotic properties. HDAC 6 localizes to perinuclear regions and deacetylate the 
oncogenic protein, blocking apoptosis in cancer cells [17]. All of these facets, make HDAC 
6 a prime target for anticancer drugs, especially in metastatic cancer cells, but a lot is still 
unknown about the mechanisms of its involvement in cancer.  
 The multifaceted roles of HDACs in cancer, give a wide range of anticancer drug 
targets. The mechanisms of anticancer effects are not uniform, but vary with the type of 
cancer being treated and with the individual inhibitor target HDAC class. There are five 
classes of HDAC inhibitors: hydroxamic acids, short- chain fatty acids, benzamides, cyclic 
tetrapeptides, and sirtuin inhibitors [18]. As of 2017, there were four approved HDAC 
inhibitor drugs to treat cancer. The first was a hydroxamic acid called Vorinostat, or SAHA. 
Vorinostat is a pan-HDAC inhibitor approved to treat cutaneous T-cell lymphoma. 
Belinostat is also a hydroxamic acid-based pan-inhibitor, and it is approved to treat 
peripheral T-cell lymphoma. Panobinostat is similar, but it is used in the treatment of 
multiple myelomas. Romidepsin is a cyclic tetrapeptide HDAC isoform-selective inhibitor 
which selects for class I HDACs. It is approved to treat cutaneous T-cell lymphoma [18]. 
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There are many other HDAC inhibitors still undergoing various stages of trials and testing. 
One of these is Ricolinostat, a benzamide-based inhibitor, which selectively targets HDAC 
6. HDAC inhibitors have been found to induce apoptosis, alter cell migration, activate cell 
differentiation, impair tumor angiogenesis, and upregulate the expression of tumor 
suppressor genes and proteins [18].  
 In this experiment we sought to look more closely at some HDAC inhibitors and 
their effects over multiple breast cancer cell lines. Specifically, we wanted to explore the 
behavior of HDAC inhibitors known for targeting non-histone microtubule proteins in 
comparison with nuclear HDAC inhibitors and known chemotherapeutic microtubule 
stabilizer and destabilizers. We tested multiple metastases lines in order to investigate the 
possibility of cell-line dependency on HDAC inhibition.  
 
METHODS 
 BACKGROUND RESEARCH: 
The undertaking of this thesis began over two years ago in the fall semester of 2016. 
We were involved in an introductory cancer research class in which we learned more about 
cancer and its mechanisms. In the spring of that year, we began to subdivide our class into 
specific interest groups. We began planning our approach to study the effects of HDAC 
inhibition in metastatic cancer cells with literary searches of existing research and scholarly 
sources. We began looking at different HDAC inhibitors and oncological compounds of 
interest. The layout of our experiment started by focusing on existing drug treatments and 
on the National Cancer Institute Developmental Therapeutics Program NCI-60 cell line 
database, a resource which makes relevant concentration responses known for different 
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compounds on specific cell lines. Under the guidance of Dr. Zhou, we were able to look at 
the available compounds and create an experimental layout. We wanted to make sure that 
each class of classical families of HDACs were represented through an inhibiting 
compound. We used two pan-HDAC inhibitors, an inhibitor selective to class 1 HDACs, 
and an inhibitor selective for the class II HDAC 6 enzyme specifically. The HDAC 6 
inhibitors were of particular interest because of HDAC 6’s known selectivity towards non-
histone microtubule targets. We also included in our experiment known microtubule 
stabilizers and destabilizers in order to study them in conjunction with the activity of 
HDAC specific inhibition. The comparison might give a better understanding into the 
involvement of non-histone targets of HDACs such as the a-tubulin protein in 
microtubules. 
 
DRUG COMPOUNDS:  
 
Vorinostat (SAHA)  
 We purchased Vorinostat from Cayman Chemical 
Company. It was dissolved with DMSO to make a 10 mM stock 
solution. It is a pan-HDAC inhibitor 
             Figure 4 Vorinostat 
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Panobinostat  
 We purchased Panobinostat from Cayman Chemical 
Company. It was dissolved with DMSO to make 100 µM stock 
solution. It is a pan-HDAC inhibitor.  
Figure 5 Panobinostat 
           
Romidepsin 
  We purchased Romidepsin from Cayman Chemical 
Company. It was dissolved with DMSO to make a 100 µM 
stock solution. It is a selective inhibitor for class I HDACs.  
                                                                                                Figure 6 Romidepsin 
 
Ricolinostat                                                        
 We purchased Ricolinostat from Selleck Chemical  
Company. It was dissolved with DMSO to make a 10 mM 
stock solution. It is an inhibitor selective for HDAC 6. 
 
Paclitaxel (Taxol) 
 We purchased Paclitaxel from Sigma Aldrich. It was 
dissolved with DMSO to make a 10 mM stock solution. It is a 
microtubule stabilizer.                                
                                                                      Figure 8 Paclitaxel 
 
Figure 7 Ricolinostat 
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Epothilone B                                                                                           
 We purchased Epothilone B from Selleck Chemical 
Company. It was dissolved with DMSO to make a 10 mM 
stock solution. It is a microtubule stabilizer.  
 
Figure 9 Epothilone B 
 
Colchicine  
 We purchased Colchicine from Sigma Aldrich. It was 
dissolved with DMSO to make a 100 µM stock solution. It is a 
microtubule destabilizer.  
 
 Figure 10 Colchicine 
 
Vinblastine 
 We purchased Vinblastine from Sigma Aldrich. It was 
dissolved with DMSO to make a 100 µM stock solution. It is a 
microtubule destabilizer.  
  
Figure 11 Vinblastine 
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CELL LINES:  
 
We looked at the effects of HDAC inhibition over three cells lines: BOM, LM, and 
MCF-7-BOM. Both BOM and LM are derived from the triple-negative breast cancer cell 
line, MDA-MB-231. It was originally isolated over 40 years ago from a pleural effusion in 
a breast cancer patient with a metastatic relapse several years after her primary tumor 
removal [19]. MDA-MB-231 is highly selective for metastasis and has specific tissue 
dissemination selectivity to the bone and lung [20]. We are using a subpopulation derived 
from MDA-MB-231, BOM-1833, which is highly selective for metastasis to the bone when 
injected into the arterial circulation of immunodeficient mice [19]. Another derivative of 
MDA-MB-231 that we used is LM-4175, a derivative cell line, which is highly aggressive 
towards lung metastasis in mice [20]. MCF7-BOM is metastatic variant of derived from 
MCF7, a well characterized human breast cancer cell line. MCF7 is an ER positive breast 
cancer cell line that originated from a 69-year-old Caucasian female in the 1970’s [24]. 
Both the MDA-MB-231 variant lines (BoM-1833, LM-4175) and the MCF-7 variant line 
(MCF7-BoM) were cultured in Dulbecco’s modified Eagle’s media (DMEM)/F12 that 
were supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics [19]. All of the 
metastases lines used in our research were first generated by Dr. J Massagué at the Sloan 
Kettering Cancer Center, New York City, New York [19].  Our research group obtained 
all of the metastatic clones from Dr. Kounosuke Watabe at Wake Forest University [24]. 
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PREPARING STOCK AND WORKING DILUTIONS: 
 To begin preparing the compounds for testing, we removed powdered compounds 
from 4ºC and let them warm up to room temperature for weighing on an analytic balance. 
Using DMSO, dimethyl sulfoxide, we prepared 10mM stock solutions for compounds with 
the higher range of concentration (vorinostat, paclitaxel, epothilone B, and ricolinostat) and 
00 µM stock solutions for those needing a lower range (romidepsin, panobinostat, 
colchicine, and vinblastine.) Then using a serum free media, we diluted the stock solution 
to the highest tested concentration at 2x final concentration in the mother plate. We 
prepared the mother plate at 3.5x times of the required volume, since for the first round of 
viability we were working with three 96-well plates. We used a 1:10 serial dilution to 
prepare the working solutions at the lower concentrations. From the well on the mother 
plate with the highest concentration, we took same volume of solution and added it to a 
lower well in a stepwise fashion, and then we diluted it to the desired concentration using 
serum free media, achieving the desired 350 µL end volume for each well.  For example, 
we took 35 µL of the 0.1 µM solution well and put in into a well with 315 µL of serum free 
media to create 350 µL of 0.1 µM solution as seen in figure 12.  
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Figure 12 Serial Dilution in 96-well plate 
 
SRB VIABILITY ASSAY: 
Once we had our compounds and concentration ranges selected we ran several SRB 
viability assays. The SRB, or Sulforhodamine B Assay, is a rapid, sensitive, and relatively 
economical tool for looking at cell proliferation and chemosensitivity. To start the assay, 
the cells were taken out of incubator, the conditioned media removed, and the cells 
detached withtrypsin (1 ml per 10 cm plate), then the reaction stopped with 10 mL media 
that contains 10% FBS. The media used to grow the cells was RPMI-1640 with L-
glutamine supplemented with 10% FBS and penicillin and streptomycin, known as 
“complete media.” With the help of a hemocytometer to obtain average cell count, we were 
able to dilute the cells with additional 10% FBS media until we had a solution of three 
million cells per mL of media. We seeded the cells in a 96-well plate at a concentration of 
30,000 cells per well. (100uL cell solution, 100uL media). The plates were cultured at 37ºC 
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in a humidified 5% CO2/ 95% air environment for 24 hours. The cells were then treated 
with 10 µM-0.01 µM concentration scale of vorinostat, paclitaxel, epothilone B, and 
ricolinostat, and with a concentration scale of 0.1 µM - 0.0001 µM for romidepsin, 
panobinostat, colchicine, and vinblastine. The plates were incubated and removed after 48 
hours. To fix the cells, 100 µL of conditioned media was removed from each well, and 100 
µL of a 20% trichloroacetic acid (TCA) in 1x PBS solution added. These plates were set 
aside for an hour at 4ºC. The plates were washed with tap water four times and left to dry. 
To the dry wells, 75 µL of SRB (0.4% w/v in 1% acetic acid) was added and allowed to 
sit. After 10 minutes the plates were washed with 1% acetic acid three times then allowed 
to dry. To extract the dye, 100 µL of 10 mM Tris Base was added to each well, and the 
plates were gently shaken for 10 minutes on the microplate genie. Using a Spectrafluor 
plate reader and Magellan software, the plates were read at 490nm with background620 
nm absorbance. The inhibition of each compound on each cell line can be found because 
the SRB dye binds to basic amino acids in cellular proteins of the cells [21]. The 
colorimetric valuation gives an estimate of the total protein mass per well which is 
proportional to cell number per well.   
 
CLONOGENIC ASSAY: 
  Clonogenic assays are used to determine the effect of cytotoxic compounds on the 
reproductive and proliferative properties of cells. To determine the effectiveness of the 
chemotherapeutic agents used, we looked at the relative number of colonies proliferated 
over a period of ten days. We tested two cells lines, MCF7-BoM and BoM-1833. We 
looked at the effect of high and low concentrations of vinblastine, panobinostat, 
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romidepsin, SAHA, ricolinostat, paclitaxel, epothilone B, and colchicine over three the 
area six-well plates. That layout of these plates can be seen in figure 16. The cancer cells 
were seeded at 3,000 cells per well and incubated for 4 hours at 37ºC to allow the cells to 
adhere. The compounds were added with media at their respective concentrations to the 
wells for 24 hours. At that point, the compound filled media was swapped out for fresh 
(10%) FBS media with antibiotics. This was set aside for 5 days, at which time the media 
was switched out again. After 10 days, the cells were fixed with methanol and stained with 
crystal violet (1 mg/mL in 20% ethanol) in order to see the proliferation of the cells clearly. 
The concentrations of the compounds tested were chosen based on physiological relevance 
and cytotoxic potential (Table 2). 
  Table 2 Clonogenic assay tested concentrations 
  Compound High 
Concentration 
Low 
Concentration  
Paclitaxel 1.0 µM 0.1 µM 
Epothilone B 0.01 µM 0.001 µM 
Colchicine 0.1 µM 0.01 µM 
Vinblastine 0.1 µM 0.01 µM 
SAHA 10 µM 1.0 µM 
Ricolinostat 10 µM 1.0 µM 
Romidepsin 0.01 µM 0.001 µM 
Panobinostat 0.1 µM 0.01 µM 
    
COMBINATION ASSAY: 
 We looked at histone deacetylase inhibitors in combination with other relevant 
chemotherapeutic agents. The procedure we followed was very similar to that of the 
viability assay. Paclitaxel and epothilone B are both microtubule stabilizer. Romidepsin, 
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ricolinostat, and panobinostat were the HDAC inhibitors that we used. We combined the 
stabilizers with the HDAC inhibitors as seen in figure 13. We chose to test these three 
HDAC inhibitors specifically because we wanted a range of HDAC class selectivity. 
Romidepsin is the most active and found to be selective for HDAC class 1. Panobinostat 
is a good control inhibitor, because it is a pan HDAC inhibitor. Ricolinostat is selective for 
HDAC 6. The stabilizers were selected based on their clinical effectiveness. Each 
compound was tested at a concentration range based on active concentrations found on the 
NCI database and taking into consideration the highest achievable concentration in patient 
plasma concentrations. We set up the experiment hoping to gauge the activity of the two 
compounds in combination whether they be synergistic, antagonistic, or additive.  
 
 Romidepsin 
    V             V           V 
    V             V           V 
Ricolinostat 
  V             V          V 
  V             V          V 
Panobinostat 
    V              V             V           V 
    V              V             V           V 
Taxol 0nM       ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
Taxol 10nM     ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
Taxol 100 nM   ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
Taxol 1µM       ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
EpoB 0nM       ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
EpoB 10nM     ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
EpoB 100nM   ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
EpoB 1µM       ===> 0.001 µM 0.01 µM 0.1 µM 0.1 µM 1 µM 10 µM 0.0001 µM 0.001 µM 0.01 µM 0.1 µM 
 
Figure 13 Combination assay plate layout 
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RESULTS AND DISCUSSION 
 VIABILITY ASSAY RESULTS: 
The percent inhibition of the HDAC inhibitors, microtubule stabilizers, and 
destabilizers at different concentrations in different cell lines was graphed to display any 
relationship between concentration and inhibition or cell line selectivity. The graphs were 
put together using the software Prism 8 (GraphPad). 
 
 
 
 
 
 
 
 
 
 
 
  
 
None of the compounds were able to inhibit cell proliferation enough to establish 
an IC50, a measure used to indicate the concentration at which a compound can inhibit cell 
growth at one-half of the maximum inhibition. The IC50 is a commonly used tool which 
helps to measure drug activity [22]. The concentration ranges used for the compounds may 
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have been too low. In the future, more testing may help to see the effectiveness of these 
compounds at higher concentrations. While IC50 values were not achieved, we did note the 
concentration with the highest inhibitory effect for each compound over the three cell lines. 
This can be seen in Table 3. 
 Table 3 Highest average Inhibitory Concentrations over three cell lines 
 
The highlighted cells in Table 3 indicate that the highest inhibitory concentration 
is the highest concentration of the compound that was tested. This is the case for almost all 
of the compounds, suggesting that, if tested again at higher concentrations, the percent 
Inhibition may increase with concentration. The outlier of this group of compounds was 
Epothilone B, a microtubule stabilizer known for the its potency in the treatment of 
paclitaxel-resistant cells [23]. Epothilone showed inhibition even at the lowest 
concentration tested and had consistent inhibition over its tested concentration range. There 
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was not a trend to suggest a sensitivity to increasing concentration on inhibition though. 
Further testing may help to shed light onto the effect of epothilone B on these three breast 
cancer cell lines.  
 While complete inhibition was not achieved by any of the compounds, some of the 
highest inhibition percentages (74% with romidepsin) were found in the plates containing 
the MCF-7 BOM cells. The MCF-7 BoM is an ER+ cell line unlike BoM and LM which 
are both triple-negative breast cancers [24]. This may suggest that HDACs are more 
involved in the mechanisms surrounding the ER+ breast cancer than in triple negative 
breast cancer.  HDAC inhibition has been connected to the inhibition of MCF-7 breast 
cancer cells in previous studies. Specifically, their relationship involving the Akt serine-
threonine family of kinase, which signal regulation of proliferation, protein translation, and 
apoptosis [25]. The down regulation of Akt proteins is just one potential mechanism among 
many that may be associated with HDAC inhibition in ER+ breast cancer.  Many 
mechanistic properties involved with HDACs and HDAC inhibition are not well known, 
but may play a role in cancer cell proliferation.   
 Another round of viability assays was performed specifically with the BoM-1833 
cell line. The results of which can be seen in Figure 16.  
 While the mechanisms behind the HDAC inhibitors are complex and largely still 
under investigation, these viability assays show a clear effect on the tumor cells. HDAC 
inhibitors, whether it be epigenetically or through non-histone target, seem to inhibit 
tumor cell growth in most cases.  
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Figure 15 Inhibition over different drug concentrations in BOM cells. 
 These viability assays came out a little more strangely. Like the earlier, multi-cell 
line assay, none of these were able to completely inhibit the breast cancer cells and, 
therefore, IC50 values were not established. Again, these compounds should be 
subsequently evaluated again at higher concentrations. These BoM assays held a general 
pattern of increased inhibition with increased concentration, suggested by the prior results. 
The percent inhibition in general was larger in this experiment compared to the previous 
viability assay’s inhibition. This could be because of an initial decline in the health of the 
BoM cells at the start of the second round of assays or a difference in lab technique 
proficiency between the time of the two assays. There were also a couple of compounds 
that produced a dramatic drop in inhibition at higher concentrations: panobinostat and 
romidepsin. These exhibited no inhibition at their highest tested concentration. This could 
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potentially be attributed to experimental error since it directly opposes the results of the 
first viability assay and is such a dramatic change in effect. More testing would help to 
clarify these results.  
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 CLONOGENIC ASSAY RESULTS: 
               BOM                                                   MCF-7 BOM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Clonogenic Assay Plates  
 
 These clonogenic plates show that the BoM and MCF-7 BoM cell lines seem to 
react similarly to each compound concentration. These results do not support cell-line-
dependent inhibition. None of the HDAC inhibitors are effective at their lower tested 
concentrations. All of the HDAC inhibitors showed inhibition at their higher tested 
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concentration, though ricolinostat appeared not as effective as the others at its higher 
concentration. It is interesting that ricolinostat shows slightly different results than the other 
HDAC inhibitors. This could be accounted for by a change in tested concentration, but it 
is important to note that ricolinostat is the only HDAC class 2 inhibitor, being highly 
selective for HDAC 6 inhibition. These HDACs are more cytoplasmic and have more non-
histone targets [16]. The slight difference could possibly be accounted for because of 
mechanistic differences between the class 2 histones and the others. The microtubule 
stabilizers tested (paclitaxel and epothilone B) showed apparent complete inhibition at both 
high and low tested concentrations. Neither of the destabilizers tested (colchicine and 
vinblastine) completely inhibited the cells at their lower concentrations.  Colchicine 
seemed to inhibit the cells more fully than vinblastine at their higher tested concentration. 
Overall, this assay helps to assert that there is indeed a correlation between increased 
HDAC inhibitor concentration and the survival of the tumor cells.  
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COMBINATION ASSAY RESULTS: 
 
 
 
 
 
 
 
 
 
Figure 17 Combination results between Romidepsin and microtubule stabilizers 
 
This figure shows the combination between Romidepsin, a class I selective HDAC 
inhibitor and the microtubule stabilizers Paclitaxel and Epothilone B in both BOM-1833 
and MCF-7 BOM metastatic breast cancer cells. Taxol by itself in this test seems to have 
no inhibitory effect on the tumor cells. Epothilone B doesn’t appear to add to the percent 
inhibition until it reaches higher concentrations (0.1 µM.) This is a different result than can 
be seen in the viability and clonogenic assays, in which epothilone B is inhibitory at very 
small concentrations. Once romidepsin and epothilone B are combined, there seems to be 
a downward trend in cell inhibition. They appear to be slightly antagonistic towards each 
other. As higher concentration of the HDAC inhibitor are added, the inhibition in reduced. 
Taxol and romidepsin show similar antagonistic results. Both of these combination results 
are supported by the National Cancer Institute (NCI) Combination Almanac database [27]. 
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Figure 18 Combination results between ricolinostat and microtubule stabilizers 
 
 This figure shows the combination between ricolinostat, a class II HDAC 6 
selective HDAC inhibitor and the microtubule stabilizers paclitaxel and epothilone B in 
both BOM and MCF-7 BOM metastatic breast cancer cells. Again, here Taxol seems to 
not be inhibitory towards the cells by itself and epothilone only seems to be effective at 
higher concentrations. The combination bars of these graphs are abnormal, especially 
surrounding the last two concentrations groupings of both microtubule stabilizer graphs. 
The results are too sporadic and opposing to make sense. There must have been some lab 
error involving those combinations. Because of the lack of information surrounding higher 
concentrations of epothilone B and Taxol, it is hard to say what the relationship there 
appears to be between the stabilizers and HDAC 6 inhibitor. This combination should be 
rerun to find more accurate and replicable results. Although the results from this assay set 
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are hard to interpret the general trend seems to be more antagonistic. However, previous 
research has shown that the combination treatment of paclitaxel and ricolinostat will be 
synergistic in the suppression of tumor growth. In cell lines from multiple solid tumor 
lineages, combination treatment with an HDAC-6 inhibitor and paclitaxel enhanced 
inhibition of proliferation and increased cell death compared to either single compound 
alone [26.]. Along with other effects, the inhibition of HDAC 6 results in the 
hyperacetylation of α-tubulin, which increases microtubule stability. This suggests that 
inhibition of HDAC 6 by selective or pan-HDAC inhibitors could increase in efficacy when 
in combination with microtubule stabilizers [26.] 
 
Figure 19 Combination results between panobinostat and microtubule stabilizers 
 
 Figure 19 shows the combination between Panobinostat, a pan selective HDAC 
inhibitor and the microtubule stabilizers paclitaxel and epothilone B in both BOM and 
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MCF-7 BOM metastatic breast cancer cells. Taxol and epothilone B show the same trends 
of inhibition as singular compounds as in the other two combination assays. The results 
suggest an antagonistic relationship in both the panobinostat/paclitaxel and 
panobinostat/epothilone B combinations. The inhibition appears to be strongest with 0.001 
µM of panobinostat in all applications. The inhibition decreased as the concentration of the 
HDAC inhibitor increases. 
These combination assays were done in replicate with n = 2.  
In future rounds of these combinations, they would be repeated with at least n = 3 in order 
to ensure more accurate results.  
 The lack of independent inhibition from paclitaxel in all of these combinations was 
initially surprising because Taxol is an established chemotherapeutic drug. But recent 
studies have shown that while high doses of paclitaxel result in mitotic arrest, clinically 
relevant low concentrations of paclitaxel can increase multipolar spindle formation and 
subsequently increased the rate of aberrant mitosis and cell death [26]. 
 
CONCLUSIONS: 
 Using multiple experimental assays, the effects of HDAC inhibitors were tested on 
MDA-DB-231 derivatives, BOM-1833 and LM-4175 as well as on ER+ MCF-7 BOM 
metastatic breast cancer cells.  Through viability assays, curves for percent inhibition were 
produced which did not have enough inhibition to find IC50 values, but did have a strong 
trend towards a potential for increased percent inhibition with further testing at higher 
concentration ranges. The viability assay also suggested a slight selectivity of inhibition 
between HDAC inhibitors and ER+ MCF-7 BOM cells over the two triple negative MDA-
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MB-231 derivative cell lines.  Clonogenic assays supported the effectiveness of higher 
concentrations of HDAC inhibitors on the inhibition of tumor cell growth, but presented 
evidence against cell-line-dependent inhibition. When combined with microtubule 
stabilizers, paclitaxel and epothilone B, the HDAC inhibitors showed an overall 
antagonistic effect. These results indicate that HDACs may be valuable targets for anti-
cancer drugs over multiple cell lines. In future research, fluorescent protein labeling could 
be done to determine the molecular interactions involved in the inhibition of breast cancer 
cells by the HDAC inhibitors. This might better demonstrate the potential role of non-
histone microtubule targets in tumor inhibition.  
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